Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Organon (OGN)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Crispr Therapeutics AG (CRSP – Research Report) and Organon (OGN – Research Report).
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Crispr Therapeutics AG (CRSP)
Chardan Capital analyst Geulah Livshits maintained a Buy rating on Crispr Therapeutics AG yesterday and set a price target of $76.00. The company’s shares closed last Friday at $53.07.
Livshits has an average return of
According to TipRanks.com, Livshits is ranked #769 out of 12109 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $73.00 average price target, a 46.8% upside from current levels. In a report issued on January 30, Citizens JMP also maintained a Buy rating on the stock with a $80.00 price target.
See the top stocks recommended by analysts >>
Organon (OGN)
J.P. Morgan analyst Chris Schott maintained a Sell rating on Organon yesterday and set a price target of $11.00. The company’s shares closed last Friday at $7.39.
According to TipRanks.com, Schott is a 4-star analyst with an average return of
Currently, the analyst consensus on Organon is a Strong Sell with an average price target of $9.25, implying a 31.8% upside from current levels. In a report released yesterday, Bank of America Securities also maintained a Sell rating on the stock.
